NOTICE OF MAILING CHANGE
☐ Check here if you wish to discontinue receiving this publication.

☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to:

NIH Guide Distribution Center
National Institutes of Health
Room B3BE07, Building 31
Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

OFFICIAL BUSINESS
Penalty for Private Use: $300

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

VOL. 16, NO. 15, MAY 1, 1987
NOTICES

HUMAN LIVER TISSUE FOR RESEARCH AVAILABLE.............................................. 1
National Institute of Diabetes and Digestive and Kidney Diseases
Index: AVAILABLE RESOURCES

CHANGE IN ELIGIBILITY CRITERIA FOR ADAMHA FIRST PROGRAM........................... 1
Alcohol, Drug Abuse, and Mental Health Administration
Index: ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH

DATED ANNOUNCEMENTS (RFPs and RFAs AVAILABLE)

PHASE I CLINICAL TRIALS OF BIOLOGICAL RESPONSE MODIFIERS (RFP).................. 2
National Cancer Institute
Index: CANCER

A PAPILLOMAVIRUS ANIMAL MODEL FOR EVALUATION OF
EXPERIMENTAL THERAPIES (RFP)...................................................... 3
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES

DEVELOPMENT OF PROTEIN-POLYSACCHARIDE PNEUMOCOCCAL
CONJUGATE VACCINES (RFP)........................................................... 3
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES

MASTER AGREEMENT FOR THE CLINICAL EVALUATION OF
INVESTIGATIONAL ANTIPILEPTIC DRUGS (RFP)....................................... 4
National Institute of Neurological and Communicative Disorders and Stroke
Index: NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE

GENETIC BASIS OF REPRODUCTIVE DISORDERS (RFA).................................... 5
National Institute of Child Health and Human Development
Index: CHILD HEALTH AND HUMAN DEVELOPMENT

CENTERS FOR INTERDISCIPLINARY RESEARCH ON IMMUNOLOGIC DISEASES (RFA)...... 6
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES

ASTHMA AND ALLERGIC DISEASES CENTERS (RFA)...................................... 7
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES

CORE GRANTS FOR CLINICAL NUTRITION RESEARCH UNITS (CNRUs) (RFA)............ 8
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES AND DIGESTIVE AND KIDNEY DISEASES

MINORITY MENTAL HEALTH RESEARCH CENTERS........................................... 9
National Institute of Mental Health
Index: MENTAL HEALTH

ADDENDUM

RESEARCH GRANTS RELATED TO PAIN AND ANALGESIA...................................... 10
Alcohol, Drug Abuse, and Mental Health Administration
Index: ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH

ERRATUM

SOCIAL AND DEMOGRAPHIC RESEARCH ON INFANT MORTALITY AND LOW
BIRTHWEIGHT................................................................. 10
National Institute of Child Health and Human Development
Index: CHILD HEALTH AND HUMAN DEVELOPMENT
HUMAN LIVER TISSUE FOR RESEARCH AVAILABLE

P.T. 34; K.W. 0780005

National Institute of Diabetes and Digestive and Kidney Diseases

Human liver for scientific investigation is available through the National Institute of Diabetes and Digestive and Kidney Diseases, NIH supported Liver Tissue Procurement and Distribution System (LTPADS). Five regional centers have been subcontracted for the collection of livers obtained at the time of transplant for scientific investigators nationwide. Further information and proposal forms for interested investigators can be obtained from:

Harvey L. Sharp, M.D.
LTPADS
Box 279 Mayo Building
University of Minnesota Hospital
Minneapolis, MN 55455
Telephone: (612) 624-1133 or 624-2422

CHANGE IN ELIGIBILITY CRITERIA FOR ADAMHA FIRST PROGRAM

P.T. 34; K.W. 0710030, 0404000, 0785035, 1014002

Alcohol, Drug Abuse, and Mental Health Administration

This notice is to announce that recipients of Research Scientist Development, Level I (K01), Academic Investigator (K07), Clinical Investigator (K08) and Physician Scientist Awards (K11) may apply for and receive FIRST awards from ADAMHA providing they meet other eligibility criteria for FIRST awards. The purpose of this eligibility change is to recognize that the K awardees are typically among the most promising developing scientists and therefore it is appropriate to afford them the opportunity, when they are ready for independent investigation, to receive an award which provides a special support mechanism for new investigators.

The FIRST award is intended to provide newly independent investigators with a sufficient period of initial research support to demonstrate their research creativity, productivity and future promise. It is a research project award which must represent at least 50 percent effort of the investigator. The various K awards mentioned above have as their goal supporting the development of scientists into independent investigators, including a period of supervised research.

K01, K07, K08 and K11 recipients who apply for FIRST awards will be judged, as are other FIRST applicants, on the basis of whether they are ready for independent investigation. Accordingly, it would not be permissible for an individual to simultaneously submit an application for both a K and a FIRST application. Rather, an individual who is a recipient of a K award must have held that award for a sufficient period of time to be able to demonstrate readiness to undertake an independent research project. Other conditions of both the FIRST and K awards will apply. Once an investigator receives a FIRST award, he or she will not be able to receive a research allowance under the K award.

This change in eligibility criteria for the FIRST program will be effective for applications submitted beginning with the June 1, 1987 receipt date.

For copies of announcements for the K programs mentioned in this notice or the FIRST program, contact the following:

Anne Cooley
National Institute of Mental Health
Extramural Policy Branch, DEA
5600 Fishers Lane, Room 9-95
Rockville, Maryland 20857
Telephone: (301) 443-4673

National Clearinghouse on Alcohol Information
1776 Plaza
E. Jefferson Street
Rockville, Maryland 20852
Telephone: (301) 468-2600
PHASE I CLINICAL TRIALS OF BIOLOGICAL RESPONSE MODIFIERS

RFP AVAILABLE: NCI-CM-87215-18

P.T. 34; K.W. 0740015, 0755015, 0760045, 0710100

National Cancer Institute

The Biological Response Modifiers Program (BRMP) of the Division of Cancer Treatment (DCT), National Cancer Institute, is seeking organizations to perform Phase I clinical trials of biological response modifiers (BRMs), and, in addition, to have the capability to perform basic immunologic, pharmacokinetic and clinical monitoring as required by the following tasks.

Task A: Phase I Clinical Studies of Monoclonal Antibodies or Monoclonal Immunoconjugates in Cancer.

This theoretical protocol shall be a Phase I IB clinical and laboratory evaluation of an actual unconjugated monoclonal antibody. The theoretical protocol should address, but is not limited to, the following:

Objectives:

1.1 To determine the optimal biological dose of (investigational agent x).
1.2 To determine the toxicities of (investigational agent x).
1.3 To determine the effects of (investigational agent x) on tumor response.

Task B: Phase I Clinical Studies of Cytokines and Immunomodulators Alone or in Combination with Other Anti-Cancer Modalities in Cancer Patients.

This theoretical protocol shall be a Phase IB clinical and laboratory evaluation of an actual Cytokine of Immunomodulator other than an Interferon of Interleukin-2.

The theoretical protocol should address, but is not limited to, the following:

Objectives:

1.1 To determine the optimal biological dose of (investigational agent x).
1.2 To determine the toxicities of (investigational agent x).
1.3 To determine the effect of (investigational agent x) on tumor response.

Approximately 8 awards will be made for this study. It is anticipated that cost-reimbursement, 5 year incrementally-funded contracts will be awarded as a result of the RFP.

A preproposal conference is planned for prospective offerors for the purpose of providing information which may be helpful in the preparation of proposals and to answer any questions which offerors may have regarding this solicitation. Complete instructions will be provided in the RFP package.

This synopsis is not a request for proposal. The RFP for the above described work will be available to interested offerors on or about May 5, 1987.

All responsible sources may submit a proposal which shall be considered by the agency.

Requests for the solicitation must reference RFP NCI-CM-87215-18 and should be addressed to:

Catherine V. Baker
Contract Specialist
National Cancer Institute
Research Contracts Branch, TCS
Blair Building, Room 212
Bethesda, Maryland 20892
Telephone: (301) 427-8737
A PAPILLOMAVIRUS ANIMAL MODEL FOR EVALUATION OF EXPERIMENTAL THERAPIES

RFP AVAILABLE: NIH-NIAID-MIDP-88-2

P.T. 34; K.W. 1002045, 0715125

National Institute of Allergy and Infectious Diseases

The Development and Application Branch of the Microbiology and Infectious Disease Program, National Institute of Allergy and Infectious Diseases, is soliciting proposals from organizations having the capabilities and facilities to employ an appropriate papillomavirus animal model system to screen the efficacy of antiviral substances and provide badly-needed basis information on the natural history and pathogenesis of papilloma virus infections.

Current treatment for papillomavirus infection is limited to topical therapies which destroy tissue, are limited to visible lesions, and are associated with unacceptably high recurrence rates. Consequently, there is a clear need to identify effective systemic chemotherapeutic agents. The availability of animal model systems mimicking human papillomavirus infection, as well as the recently achieved increased molecular understanding of the virus, make it feasible to initiate a program to identify therapeutic agents for these infections.

This is an announcement of a new solicitation for an anticipated Request for Proposal (RFP). RFP-NIH-NIAID-MIDP-88-2 has been available since March 24, 1987, and proposals will be due by close of business on July 6, 1987. One (1) award is anticipated although the Government reserves the right to make more than one award for a contract period of approximately five (5) years. Requests for the RFP should be directed to:

Thomas C. Porter
Contract Management Branch
National Institute of Allergy and Infectious Diseases
Westwood Building, Room 707
Bethesda, Maryland 20892

Your request should reference RFP-NIH-NIAID-88-2. Please provide this office with two self-addressed mailing labels. Telephone inquiries will not be honored and all inquiries must be in writing and addressed to the above stated office.

This advertisement does not commit the Government to make an award.

DEVELOPMENT OF PROTEIN-POLYSACCHARIDE PNEUMOCOCCAL CONJUGATE VACCINES

RFP AVAILABLE: NIH-NIAID-MIDP-88-5

P.T. 34; K.W. 0740075, 0745045

National Institute of Allergy and Infectious Diseases

The Development and Application Branch of the Microbiology and Infectious Disease Program of the National Institute of Allergy and Infectious Diseases is soliciting proposals from organizations having the capabilities and facilities to: (1) isolate and purify capsular polysaccharide antigens from selected pneumococcal serotypes; (2) develop modified pneumococcal capsular antigens, using conjugation procedures, which can induce anti-Streptococcus pneumoniae capsular polysaccharide antibodies in infants; (3) perform animal testing for the vaccines safety and potency; and (4) provide sufficient doses of vaccine for human safety, immunogenicity, and efficacy testing.

This is an announcement for an anticipated Request for Proposal (RFP). RFP-NIH-NIAID-MIDP-88-5 will be issued on or about May 1, 1987, and proposals will be due by close of business June 30, 1987. One (1) award is anticipated for a contract period of approximately three (3) years. Requests for the RFP should be directed to:

Thomas C. Porter
Contract Management Branch
National Institute of Allergy and Infectious Diseases
Westwood Building, Room 707
Bethesda, Maryland 20892
Your request should reference NIH-NIAID-MIDP-88-5. Please provide this office with two self-addressed mailing labels. Telephone inquiries will not be honored and all inquiries must be in writing and addressed to the office listed above.

This advertisement does not commit the Government to make an award.

MASTER AGREEMENT FOR THE CLINICAL EVALUATION OF INVESTIGATIONAL ANTI-EPILEPTIC DRUGS

MASTER AGREEMENT ANNOUNCEMENT/RFP AVAILABLE: MAA-RFP-NIH-NINCDS-87-10

P.T. 34; K.W. 0715060, 0740020, 0710100

National Institute of Neurological and Communicative Disorders and Stroke

The Epilepsy Branch (EB) of the Convulsive, Developmental, and Neuromuscular Disorders Program (CDNDP), NINCDS plans to reissue Master Agreement Announcement (MAA)/RFP entitled "Master Agreement for the Clinical Evaluation of Investigational Antiepileptic Drugs" with the intent of seeking new sources and enlarging the pool of current Master Agreement holders who are capable of performing clinical evaluations of investigational antiepileptic drugs. Current Master Agreement (MA) holders under this program are not required to respond to this RFP, unless they want to be considered for a particular study category for which they are not currently qualified. The antiepileptic drugs to be clinically evaluated will have been selected from the EB's Antiepileptic Drug Development (ADD) Program. Under this program, an MA holder will be qualified to compete for future tasks, i.e., the clinical evaluation of drugs in accordance with specific protocols as defined within the following study categories:

Category 1: In normal male volunteers: (a) an indication of tolerance, safety and side effects and (b) estimates of pharmacokinetic parameters following administration of single or multiple doses of the investigational drug.

Category 2: In patients with uncontrolled seizures: (a) an indication of tolerance, safety and side effects and (b) an estimation of possible drug interactions and pharmacokinetic parameters.

Category 3: In patients with uncontrolled seizures: evaluation of the efficacy and safety of the investigational drug in controlled clinical trials.

An MA is an agreement issued to sources who respond to MAA/RFPs and who are judged to be qualified to compete for future tasks issued under the general study areas described in the MA. These agreements contain general terms, conditions and parameters of performance for a particular study category for which the organization is deemed qualified, but do not contain any specific work task, period of performance for a specific work task, nor funding commitment. Award of an MA under this RFP will certify an offeror as having demonstrated that they have the facilities, staff expertise, and access to adequate study populations necessary to perform and compete for future drug evaluation studies within one or more of the categories indicated above. Competition for specific clinical investigational studies will be restricted to all qualified MA holders. Successful MA competitors for futures tasks will be awarded MA Orders (MAO).

An MA0 is a bilateral contract and operational addendum to an MA. It includes a definitized Statement of Work and outlines the specific performance requirements, delivery schedule and funding for the study task.

Award of MAs under this RFP will be valid through September 30, 1991. Once awarded an MA, holders will be required on an annual basis to assure that the the capabilities of the organization that led to issuance of an MA initially are still valid and remain in place.

All responsible sources may submit a proposal, which shall be considered by the NINCDS, covering one, two or all three of the study categories mentioned above. Review of MA proposals will be conducted by the Scientific Review Branch, NINCDS. The technical merit of each proposal will be evaluated in terms of the study requirements with emphasis on the scientific and administrative capabilities of prospective offerors. Offerors must be able to provide concise information regarding their capability to accrue the required number of qualified subjects specified for each category. The technical evaluation shall also include consideration of the offeror's available personnel, facilities and equipment and the...
suitability of the proposed research plans and strategies to achieve the study objectives. It is anticipated that as a result of this MAA/RFP, a number of new sources will be awarded MAs and added to the current pool of MA holders.

MAA/RFP No. NIH 87-10 will be issued on or about May 1, 1987, with responses due after 60 days thereafter. Copies of the MAA/RFP may be obtained from the office identified below. Please supply with your request two (2) self-addressed mailing labels.

Ms. Donna Rothstein
Contract Specialist
National Institute of Neurological and Communicative Disorders and Stroke
Federal Building, Room 90
7550 Wisconsin Avenue
Bethesda, Maryland 20892

GENETIC BASIS OF REPRODUCTIVE DISORDERS

RFA AVAILABLE: 87-HD-08
P.T. 34; K.W. 0413002, 1002019
National Institute of Child Health and Human Development
Application Receipt Date: August 3, 1987

The Reproductive Sciences Branch (RSB) of the Center for Population Research (CPR) of the National Institute of Child Health and Human Development (NICHD) is inviting research grant applications investigating the genetic basis of reproductive disorders. This RFA is the first NICHD announcement in the reproductive genetics area to be specifically focused on aberrant genetic mechanisms causally associated with infertility or sterility in mammals. While a considerable variety of functional defects in the mammalian reproductive system have been reported to be genetically determined, the precise nature of the genetic system(s) involved remains unknown in all but a few instances. Applications responsive to the intent of this RFA will focus on defective genetic mechanisms causally associated with mammalian infertility or sterility. The scope of these studies could include, for example, model studies on the establishment or maturation processes of gonadal germ cells involving ovarian or testicular determining factors or genes, factors or genes associated with oogenesis or spermatogenesis failure, or genetic factors or genes controlling meiosis. The scope would also include studies on the genetic basis of familial aggregates of polycystic ovary disease, endometriosis, chronic anovulation, or other ovarian or testicular dysfunctions directly related to infertility. Responsive applications will propose to use the most current techniques of modern molecular genetics to define the gene(s) involved, characterize their structural/regulatory role in the mechanism and clarify the biological consequences of the defective gene product(s).

The RFA label obtained from the NIH staff person listed below must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review.

It is anticipated that up to eight (8) awards will be made as a result of this announcement through the grant-in-aid (R01) mechanism used by the NICHD. For a copy of the detailed RFA fully describing the specific areas of research sought, contact the following:

Michael E. McClure, Ph.D.
Reproductive Sciences Branch
Center for Population Research
National Institute of Child Health and Human Development
Room 7C33, Landow Building
National Institutes of Health
Bethesda, Maryland 20892
Telephone: (301) 496-6515
CENTERS FOR INTERDISCIPLINARY RESEARCH ON IMMUNOLOGIC DISEASES

RFA AVAILABLE: 87-AI-15

P.T. 04, 34; K.W. 0710070, 1002004, 1002008, 0710075, 0710100, 0715120, 0715015

National Institute of Allergy and Infectious Diseases

Application Receipt Date: October 15, 1987

BACKGROUND INFORMATION

The Clinical Immunology and Immunopathology Branch of the Immunology, Allergic and Immunologic Diseases Program of The National Institute of Allergy and Infectious Diseases (NIAID) supports research on the cellular and molecular mechanisms of immunologic diseases and the application of this knowledge to clinical problems. For this purpose, six Centers for Interdisciplinary Research on Immunologic Diseases (CIRID) are currently funded. This request for applications (RFA) is intended to encourage the development of new applications from collaborative basic science and clinical investigative groups and to coordinate the submission of new CIRID applications.

RESEARCH GOALS AND SCOPE

Since its inception in 1978, NIAID's fundamental objective for the CIRID program remains unchanged: acceleration of the application of knowledge on the immune system emerging from relevant biomedical sciences to clinical investigations concerned with asthma, allergic diseases, and immunologically mediated disorders. The scope of these CIRIDs is intended to include studies of all aspects of immunologic responses aimed at defining etiological factors and pathogenetic mechanisms.

Research approaches in this area include basic and clinical immunology studies of acquired and inherited diseases associated with dysfunctions of the immune system (AIDS and Childhood Immune Deficiencies); immunopathology studies of the genetics, cytology, biochemistry, physiology, and pharmacology of the immune system and its disorders (autoimmune disorders; immune relationships in diabetes, acute and chronic inflammation (mediators, anti-inflammatory agents, chemistry and disorders of complement system, and mechanisms of phagocytosis); and investigations concerned with allergic and hypersensitivity mechanisms (asthma, allergic disorders and drug reactions).

In addition, a unique feature of the CIRID program is a requirement to implement educational or community activities. Within the research framework of the Center, a variety of outreach and demonstration projects may be supported. Overall, each component project supported under the CIRID grant, whether for basic research, clinical research or outreach demonstration projects, it is expected to contribute to, and be directly related to, the overall common goal; the projects should demonstrate an essential element of unity and interdependence.

MECHANISM OF SUPPORT

CIRID grants are awarded to an institution on behalf of a program director for support of a broadly based, multi-disciplinary, long-term research program which may have a specific objective or basic theme, or may involve the integration of several themes. A CIRID generally involves the organized efforts of groups of investigators who conduct research projects related to the overall program and of certain core resources shared by individuals where the sharing facilitates the total research effort of the Center. The NIAID plans to award at least two CIRID grants during fiscal year 1988, depending on the availability of funds.

STAFF CONTACT

A more detailed RFA may be obtained from:

Robert A. Goldstein, M.D., Ph.D
Chief, Clinical Immunology and Immunopathology Branch, IAIIDP
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Westwood Building, Room 755
Bethesda, Maryland 20892
Telephone: (301) 496-7104
Prospective applicants are encouraged to submit a one-page letter of intent that includes a descriptive title of the proposed research and identification of any other participating institutions. The NIAID requests such letters by June 15, 1987, for the purpose of providing an indication of the number and scope of applications to be received. A letter of intent is not binding. It will not enter into the review of any application subsequently submitted and is not a requirement for application. Letters of intent and inquiries should be directed to Dr. Goldstein at the address shown above.

The RFA label obtained from the NIH staff person named above must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review.

ASTHMA AND ALLERGIC DISEASES CENTERS

RFA AVAILABLE: 87-AI-17

P.T. 04, 34; K.W. 0715110, 0710070, 0765035, 1002019, 1003002, 0710100, 0715185

National Institute of Allergy and Infectious Diseases

Application Receipt Date: October 15, 1987

BACKGROUND INFORMATION

The Asthma and Allergy Branch of the Immunology, Allergic and Immunologic Diseases Program of the National Institute of Allergy and Infectious Diseases (NIAID) sponsors fundamental and clinical research concerned with asthma, allergic and immunologic diseases and with relevant mechanisms of hypersensitivity and inflammation. For this purpose, twelve Asthma and Allergic Diseases Centers (AADC) are currently funded; support for four is scheduled to conclude in 1988. This request for applications (RFA) is intended to encourage submissions from clinical investigative groups meeting the criteria and requirements for an AADC and to coordinate review of new and renewal applications thus providing equitable opportunity for both to compete for funds currently available for this programmatic activity.

RESEARCH GOALS AND SCOPE

The fundamental objective of the NIAID's AADC program is to foster acceleration of the application of knowledge on the immune system emerging from relevant biomedical sciences to clinical hypersensitivity disorders. Especially sought as the requisite factors within a participating institution are quality research in (a) basic science(s), (b) clinical investigation supported by adequate clinical facilities and staff expertise in diagnosis and management of asthmatic and allergic patients, and (c) access to (an) appropriate patient population(s) within a suitable academic/investigative environment designed to favor multidisciplinary interaction.

The scope of the AADC program represents an effort to foster collaborative approaches that will integrate basic concepts in allergy, immunology, pathophysiology, genetics, microbiology, biochemistry, biostatistics, bioinstrumentation, computer science and pharmacology into clinical investigations, which, in addition to the fields of allergy and clinical immunology, may include such areas as dermatology, rheumatology, infectious diseases, pulmonary medicine, hematology and otorhinolaryngology, when a high degree of relevance to immunology exists. Because the role of hypersensitivity and immune-related inflammatory mechanisms has become increasingly evident in disorders of the skin, immunodermatologic studies are especially encouraged within an AADC. Because of the alarming increase in asthma mortality since 1979, studies are also sought to examine this trend.

Program objectives are: to encourage collaboration between basic and clinical scientists; to provide a research environment favorable for such interactions; and to implement clinical application of adequately tested research findings and procedures.

In addition, a feature of the AADC program is the opportunity for directors to implement educational or community activities. Within the research framework of the center, a variety of outreach and demonstration projects may be supported.

MECHANISM OF SUPPORT

AADC grants are awarded to an institution on behalf of a program director for the support of a broadly based, multidisciplinary, long-term research program which may have a specific objective or basic theme, or may involve the integration of several
themes. An AADC generally involves the efforts of groups of investigators who conduct research related to the overall program objective. The grant can provide support for the projects and for certain core resources shared by individuals where the sharing facilitates the total research effort. Each component project supported under an AADC grant is expected to contribute to, and be directly related to, a common theme; the component projects should demonstrate an essential element of unity and interdependence. In fiscal year 1988, the NIAID plans to fund at least four new or competing renewal Asthma and Allergic Disease Center applications, depending on the availability of funds.

STAFF CONTACT

A more detailed RFA may be obtained from:

Dorothy D. Sogn, M.D.
Chief, Asthma and Allergy Branch
Immunology, Allergic and Immunologic Diseases Program
National Institute of Allergy and Infectious Diseases
Westwood Building, Room 752
Bethesda, Maryland 20892
Telephone (301) 496-8973

Prospective applicants are encouraged to submit a one-page letter of intent that includes a descriptive title of the proposed research and identification of any other participating institutions. The NIAID requests such letters by June 15, 1987, for the purpose of providing an indication of the number and scope of applications to be received. A letter of intent is not binding. It will not enter into the review of any application subsequently submitted and is not a necessary requirement for application. Letters of intent and inquiries should be directed to Dr. Sogn at the above address.

The RFA label obtained from the NIH staff named above must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review.

CORE GRANTS FOR CLINICAL NUTRITION RESEARCH UNITS (CNRUs)

RFA AVAILABLE: 87-DK-08

P.T. 34; K.W. 0710095, 0502028, 0730050

National Institute of Diabetes and Digestive and Kidney Diseases
National Institute on Aging

Application Receipt Date: November 16, 1987

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute on Aging (NIA) invite applications for a Clinical Nutrition Research Unit (CNRU) grant to be awarded in Fiscal Year 1988. The award of one CNRU Grant is anticipated in Fiscal Year 1988.

A CNRU is an integrated array of research, educational, and service activities that is oriented toward human nutrition in health and disease. A research core center grant is awarded to facilitate the planning and coordination of the activities of the CNRU primarily by providing funding for core facilities and associated staff that serve the various projects of the CNRU on a shared basis.

ESSENTIAL COMPONENTS OF A CNRU

A CNRU, at a minimum, must comprise the following seven components which also should have other sources of support such as a regular NIH research grant (R01), NIH FIRST Award (R29), NIH Program Project (P01), NIH Individual Fellowship (F32), and the NIH Institutional National Research Service Award (T32) or other Federal and non-Federal sources:

1. Research with human subjects and populations;
2. Laboratory investigations;
3. Research training (funds to be derived from other sources);
4. Shared facilities and research services;
5. Education programs for medical students, house staff, practicing physicians, and allied health personnel (funds to be derived from other sources);
6. Research components of nutritional support services; and
7. Public information activities (funds to be derived from other sources.)

Funds to support components 3, 5, and 7 may not be requested as part of an application in response to this announcement.

Potential applicants are urged to submit a letter of intent regarding their application. The letter of intent is non-binding and is not a precondition for an award. In addition, the general description of a Core Center, copies of Core Center Guidelines, a more detailed RFA and consultation may be obtained from:

Van S. Hubbard, M.D., Ph.D. Ralph L. Bain, Ph.D.
Director, Clinical Nutrition Program Director, Digestive Diseases Centers and Assistant
Research Units Program Program Director for CNRUs
Westwood Building Room 3A18 Westwood Building, Room 3A15B
Bethesda, Maryland 20892 Bethesda, Maryland 20892
Telephone: (301) 496-7823 Telephone: (301) 496-9717

For information concerning NIA research interests in nutrition contact:

Ann Sorenson, Ph.D.
Program Director for the NIA Nutrition Program
Building 31, Room 5C-21
9000 Rockville Pike
Bethesda, Maryland 20892
Telephone: (301) 496-1033

The RFA label obtained from the NIH staff persons named above must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review.

MINORITY MENTAL HEALTH RESEARCH CENTERS

P.T. 04, 34, FF; K.W. 0715095, 0710030

National Institute of Mental Health

Application Receipt Date: October 1, 1987

The National Institute of Mental Health announces the availability of grants to establish Minority Mental Health Research Centers, announcement no. MH-87-02, to support coordinated, multidisciplinary research on the mental health problems and needs of minority populations. Subject to availability of funds, the Institute will award grants to study the following minority populations: American Indians, Asian Americans, Blacks, Hispanics, and Native Hawaiians and Pacific Islanders. Support may be requested for up to 5 years. The overall research plan must be clearly defined for the period of support. Applications in response to this announcement will be accepted under the single receipt date of October 1, 1987. Potential applicants are expected to submit a letter of intent no later than June 1, 1987, that is no longer than 10 pages. The letter of intent should be sent to:

Dr. Freda K. Cheung
Chief, Minority Research Resources Branch
Division of Biometry and Applied Sciences
National Institute of Mental Health
5600 Fishers Lane, Room 18-101
Rockville, Maryland 20857
Telephone: (301) 443-3724
ADDENDUM

RESEARCH GRANTS RELATED TO PAIN AND ANALGESIA
P.T. 34; K.W. 0715150, 0785015, 0710100

Alcohol, Drug Abuse, and Mental Health Administration

The National Institute of Mental Health (NIMH) was inadvertently omitted from the program announcement when it was originally published in the NIH Guide for Grants and Contracts on February 6, 1987, Volume 16, No. 5, pages 6-10. Applicants who are interested in applying for support from NIMH under the subject program announcement should contact:

Dr. Susan I. Blumenthal
Chief, Behavioral Medicine Program
National Institute of Mental Health
5600 Fishers Lane, Room 11C-06
Rockville, Maryland 20857
Telephone: (301) 443-4337

ERRATUM

SOCIAL AND DEMOGRAPHIC RESEARCH ON INFANT MORTALITY AND LOW BIRTHWEIGHT
RFA AVAILABLE: 87-HD-06
P.T. 34; K.W. 0403020, 0404000, 0413001

National Institute of Child Health and Human Development

Application Receipt Date: June 15, 1987

Applicants who have received a mailing of the full RFA announced in the Guide (Vol. 16, No. 11, March 20, 1987) are advised to note that the receipt date is June 15, 1987, not May 15, 1987, as stated in the full RFA.